Antiretroviral Therapy Journal Articles

• Eight Weeks of Antiviral Therapy for Recent HCV Infection Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?
  Journal of Viral Hepatitis, October 2018
• Trends in Diagnosis and Prevalence of HIV Among MSM A large proportion of diagnosed HIV infections in the US can be attributed to male-to-male sexual contact. What are the latest trends in this population?
  Morbidity & Mortality Weekly Report, October 2018
• Risk of HIV Transmission Through Biting or Spitting A better understanding of the possible transmission of HIV through spitting and biting could have important implications for prevention strategies.
  HIV Medicine, October 2018
• Antiretroviral Therapy and Brain Aging Changes in HIV Is antiretroviral therapy for HIV associated with aging-related cerebral degenerative changes? Which drugs may cause these adverse effects?
  AIDS, October 2018
• RBV Dosing in HCV Receiving OBV/PTV/r and DSV With RBV This analysis describes the clinical management of ribavirin dosing among HCV patients receiving a direct-acting antiviral regimen. When should dose modifications be considered?
  Liver International, October 2018
• Differences in Cognitive Function in Women and Men With HIV In this paper, the authors examine the sex differences in HIV-related cognitive dysfunction.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, September 2018
• Transition From Pediatric to Adult Care in Perinatal HIV A new study evaluates the outcomes before and after the transition from pediatric to adult care among patients with perinatal HIV infection.
  AIDS, September 2018
• Opportunistic Infections, Cancers and Mortality in AIDS How have improvements in combination antiretroviral therapy impacted the incidences of AIDS-related opportunistic infections and malignancies?
  HIV Medicine, September 2018
• Pregnancy Outcomes, Infant Growth Among PrEP Exposed Babies Does HIV preexposure prophylaxis use during pregnancy adversely impact outcomes and infant growth?
  AIDS, September 2018
• Oral Health and Health-related QoL in HIV Patients This study aimed to evaluate the oral health and HRQoL of HIV/AIDS patients undergoing antiretroviral therapy.
  BMC Oral Health, September 2018
• HIV: Ageing, Cognition and Neuroimaging at 4-Year Follow-Up What have we learned about the impact of HIV infection on neurocognitive ageing?
  HIV Medicine, September 2018
• BMI and the Risk of Non-AIDS Events and All-Cause Mortality A new study explores the possible relationship between BMI and the risk of certain outcomes among HIV-infected individuals receiving ART.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, August 2018
• First-Line ART With EFV or RPV Plus TDF/FTC How do these first-line combination antiretroviral therapy regimens compare in terms of tolerance and durability?
  HIV Medicine, August 2018
• Updates in the Treatment of Active and Latent Tuberculosis Get up-to-date on the latest advances in the treatment of pulmonary tuberculosis.
  Seminars in Respiratory and Critical Care Medicine, August 2018
• Pharmacokinetics of TAF When Used With Other Antiretrovirals How might other antiretroviral agents for the treatment of HIV impact the pharmacokinetics of tenofovir alafenamide?
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, August 2018
• Novel Nonmonetary Incentives to Promote HIV Testing Do these novel incentive strategies help increase the rates of HIV testing among men?
  AIDS, August 2018
• Switch to Lamivudine Plus Dolutegravir in Suppressed HIV-1 Is a switch to this dual regimen an effective treatment strategy for HIV-1 infected patients with viral suppression?
  HIV Medicine, August 2018
• Updated Isoniazid-Rifapentine Regimen to Treat Latent TB Review the latest CDC recommendations for the treatment of latent tuberculosis infection in adults and children.
  Morbidity & Mortality Weekly Report, July 2018
• Real-world Use of Elbasvir-Grazoprevir in Chronic HCV This retrospective analysis evaluated outcomes of hepatitis C patients treated with elbasvir-grazoprevir with or without ribavirin in clinical practice settings in the United States.
  Alimentary Pharmacology & Therapeutics, July 2018
• HIV-1 Group P Infection: Towards a Dead-End Infection? HIV-1 group P infections are extremely rare, but could they evolve towards a dead-end infection?
  AIDS, July 2018